Roche reveals full positive data for Hemlibra in key hemophilia A indication

Switzerland’s Roche (ROG: SIX) and its  majority-owned Japanese subsidiary Chugai Pharmaceutical (TYO: 4519) have released full data from Phase III studies testing Hemlibra (emicizumab) as a treatment for hemophilia A.

The HAVEN 3 and HAVEN 4 trials are evaluating Hemlibra as a prophylactic therapy, administered every week or every two weeks in people with hemophilia A without factor VIII inhibitors.

The firms say that the data, which will be presented at the World Federation of Hemophilia in Glasgow, show substantial and clinically meaningful reductions in bleeds, as well as clinically meaningful control of bleeding in people with or without factor VIII inhibitors.